Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.42 |
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720067 | 0.94 | TDP1 (0.43) | RAB9ANPC1TDP1SMN1; SMN2LMNA | |
| SCHEMBL717983 | 0.88 | NPC1 (0.39) | RAB9ANPC1TDP1SMN1; SMN2LMNA | |
| SCHEMBL719158 | 0.87 | NPC1 (0.38) | RAB9ANPC1TDP1SMN1; SMN2LMNA | |
| SCHEMBL719915 | 0.83 | NPC1 (0.45) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL718240 | 0.82 | NPC1 (0.40) | RAB9ANPC1TDP1LMNAMAPT | |
| SCHEMBL720498 | 0.82 | CASP3 (0.40) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL718650 | 0.82 | NPC1 (0.35) | RAB9ANPC1TDP1KDM4EALDH1A1 | |
| SCHEMBL717554 | 0.81 | NPC1 (0.34) | RAB9ANPC1TDP1KDM4EALDH1A1 | |
| SCHEMBL10249389 | 0.81 | NPC1 (0.38) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL720892 | 0.81 | F11 (0.33) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RAB9A 2454/4885NPC1 902/4885TDP1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.